1 / 42

Adnexal Mass In Pregnancy

Adnexal Mass In Pregnancy. Gari Gynecologic Oncology. Incidence: 1:200 pregnancies. 1:1000 F will undergo lap. For pelvic mass. Increased detection (U/S). The commonest are - Teratomas - Cysadenomas

morrison
Download Presentation

Adnexal Mass In Pregnancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Adnexal Mass In Pregnancy Gari Gynecologic Oncology

  2. Incidence: 1:200 pregnancies. • 1:1000 F will undergo lap. For pelvic mass. • Increased detection (U/S). • The commonest are - Teratomas - Cysadenomas - Functional / C. Luteum • 5% of adnexal masses are malignant. • Ovarian cancer incidence 1:70 F. • 1:25000 deliveries (1:800 adnexal masses).

  3. Ovarian Malignancies in Pregnancy: • Germ cell tumors (45%) : Dysgerminoma . • Epithelial tumors (37.5%), especially LMP tumor. • Sex cord–stromal tumors (10%) • Miscellaneous pathologies (7.5%) Solid Tumors In Pregnancy: Luteoma, Fibroma, Mature cystic teratomas and Krukenberg tumor.

  4. Investigations: • U/S (30% PPV) • +/- MRI • Size • Unilateral/Bilateral • Locularity/Septations • Simple/Complex • Papillary Excrescence / nodules • Omental disease/ascites • RI

  5. Tumor markers: • Ca-125 : • LDH • Alk. Phos. • HCG • AFP • Inhibin • Others (Ca 15-3, Ca 19-9, CEA).

  6. Potential complications • Torsion (ante / post partum) occurs in < 7 %, it is higher in teratoma (19%). • Rupture. • Hemorrhage. • Obstruction during labor. • Suspicion of malignancy.

  7. Management - Obstetrician / MFM + Gyn Onc. + Neonatologist - The mother is always first priority (role #1). Factors affects your management: • GA. • U/S / MRI appearance. • Size + interval change over time. • Symptoms.

  8. A- Adnexal mass Non Reassuring appearance: B- Adnexal mass with Reassuring appearance: * reproductive age group • Non pregnant patient / a symptomatic : • Pregnant patient / a symptomatic : • if < 5 cm observe (80-90% may resolve) • If > 5 cm operate … when ??? • (14 – 16 weeks)

  9. Corpus luteum support (8-10 weeks). • Risk of SAB is up to 18% (1st trimester). • Reduced risk to 4-5% if done after 14 weeks. • Consider progesterone supplement (PV/IM). • Consider steroids in elective surgery (24-34weeks) • Emergency Sx. Is associated with worse pregnancy out come. • Always explain the risk/complications to the patient.

  10. Maternal & Fetal risks: • fetal organogenesis are first trimester events. • Newer inhalational anesthetic agents are not teratogenic. • Regional anesthesia is preferred during pregnancy. • Preterm labor (up to 9%) during the 3ed trimester. • Erroneous causal associations in the patient's mind between surgery/anesthetic agents and common first trimester adverse outcomes ( eg, miscarriage, vaginal bleeding, structural anomalies )

  11. Relative incompetence of the GE sphincter increases the risk for pulmonary aspiration (Aspiration Pneumonia). • The basal metabolic rate and functional residual capacity thus hypoxemia is likely to develop rapidly during the period of apnea (induction of GA). • Minute ventilation by 50%. • TV • Expiratory reserve volume and residual volume • RR • Forced expiratory volume (FEV1)

  12. Supine hypotensive syndrome (15 deg. Lateral tilt) • VTE disease. • Other surgical risks (bleeding, infection, visceral injuries). Operative Techniques: • Always document fetal viability before and after SX. • Cont. FHM/Toco if possible (intra-op) & RR. • If non reassuring FH consider : • Check the position. • Maintaining maternal normocarbia. • Correct hypovolemia. • Increase maternal inspired oxygen concentration.

  13. Be prepared to perform an emrg. C/S if needed. A - Laparoscopy : • Is an option (not the standard of care). • Experienced surgeon, difficult exposure, potential for conversion, avoid it if ?? Malignant. • It mandates GA. • Avoid pneumo-peritomium > 15 mmHg. B - Laparotomy: • Midline / Good exposure (easy to extend). • Easy to do full staging (if needed). • Always explore other organs.

  14. Avoid uterine manipulation. • Limit your excision/resection • Avoid aspiration/drainage only. • Adnexal mass discovered during C/S should be removed. • Biopsy the contralateral ovary if abnormal. • Laparotomy is NOT CI to vaginal Delivery. • Prophylactic tocolytics : ??? • Post op. : Opiates and antiemetics. • NSAID : should be avoided, especially after 32 weeks.

  15. Post operative management: • 1 - Germ cell tumors: BEP / ?? Rad therapy • 2 - Epithelial tumors: Carbo / Taxol 2&3ed T • 3 - Tumor of LMP : depend on the implants. • Most of the chemotherapeutic agents are class -D

  16. Radiation During Pregnancy

  17. 1 Gy = 100 rad • 1 cGy = 1 rad • Threshold below which no effects are seen. if it is < 5 rads • No increased risk of any adverse effects other than slight risk of leukemia at <5 rads. • Gross congenital malformations will not be increased at doses <20 rads.

  18. 8 -25 weeks • Greatest Risk • Organogenesis • Affected cells once destroyed can not be replaced---microcephaly • Threshold 12 rad 8-15 weeks • Threshold 21 rad at 16-25 weeks

  19. Adverse Effects • Threshold phenomena in order of frequency: • Growth Retardation • Microcephaly • Mental Retardation • Microphthalmia • Pigment changes in the retina • Genital and skeletal abnormalities • Catarct • Abortion • Non-threshold phenomena: • Carcinogenesis • Dental Radiography may be associated with LBW

  20. Cervical Cancer in Pregnancy

  21. Staging • Clinical staging. • Permitted exam. / inv. : Inspection. IVP. Palpation. CXR. Colposcopy. Proctoscopy (+/- Bx). ECC. Cystoscopy (+/- Bx). Conization (Coin). Hysteroscopy.

  22. Staging (cont’d) Optional investigations ( for treatment plan ): • Lymphangiography. • Art./Venography. • Laparoscopy. Non pregnant F. • LN-FNA. • CT , US. • MRI (in pregnancy) Spread beyond the CX. Determine tumor size. LN involvement.

  23. Optional investigations , Pathological findings and report : Should not change your clinical staging

  24. RT is an option for non Sx candidates. • Similar out come but with morbidity: • Bowel • Bladder Atrophy. • Vaginal Fibrosis. Stenosis.

  25. High risk or Low risk cervical ca is it important to know ??? Post op. treatment plan: • No adjuvant treatment ? • Radiation therapy ? • Chemo-Radiation (Cisplatin +/- 5FU) ?

  26. Small Field Pelvic RT

  27. Standard field vs. Small field RT

  28. Teletherapy (External beam) - Small Field RT. - Standard Field RT. - Extended Field RT. • Brachytherapy- Intracavitary. - Interstitial.

  29. Brachytherapy: • HDR : > 1200 cGy • MDR : 200 – 1200 cGy • LDR : 40 – 200 cGy • PDR : pulses over 30 hrs.

  30. Commonly used points in Rad. Onc: Point A: • originally defined by Manchester system as a point 2 cm above the lateral fornix and 2 cm lateral to the cervical canal representing the crossing of the ureter and uterine artery (parametriem) • more currently defined as 2 cm lateral and 2 cm superior to the cervical os.

  31. Point B • Defined by Manchester system as a point at the same level as point A and extending 5 cm lateral to midline representing the obturator nodes. Point P: • Defined by Fletcher system as a point 2 cm superior to the lateral fornix and 6 cm lateral to midline representing the pelvic sidewall

  32. Commonly used points in Rad. Onc.

  33. Extended Field RT. • Para aortic LN mets is 30% in stage III compared with 7% in stage IB. • superior border is T12 – L1 interspace, and width is 10 cm. • RTOG reported a significant improvement in 5y survival for pts who had EFRT compared with had standard field RT (66% vs. 55%).

  34. Thank you

  35. Causes of elevated Ca-125

More Related